GUIDED THERAPEUTICS INC (GTHP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 300K 600K 900K Q4 '14: 65K Q1 '15: 61K Q2 '15: 60K Q3 '15: 46K Q4 '15: 42K Q4 '17: 248K Q1 '18: 231K Q2 '18: 152K Q3 '18: 121K Q4 '18: 56K Q1 '19: 70K Q2 '19: 63K Q3 '19: 62K Q4 '19: 36K Q1 '20: 18K Q2 '20: 17K Q3 '20: 93K Q4 '20: 102K Q1 '21: 102K Q2 '21: 104K Q3 '21: 46K Q4 '21: 81K Q1 '22: 86K Q2 '22: 89K Q3 '22: 73K Q4 '22: 13K Q1 '23: 30K Q2 '23: 69K Q3 '23: 66K Q4 '23: 98K Q1 '24: 82K Q2 '24: 38K Q3 '24: 38K Q4 '24: 7K Q1 '25: 1K Q2 '25: 118K Q3 '25: 178K Q4 '25: 767K Q1 '26: 767K Q2 '26: 650K Q4 '15 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-400K -200K 0 200K 400K 600K Q3 '15: -208K Q4 '15: 27K Q1 '16: 201K Q2 '16: 401K Q3 '16: 539K Q4 '17: -282K Q1 '18: -286K Q2 '18: -284K Q3 '18: -218K Q4 '18: -34K Q1 '19: -18K Q2 '19: -89K Q3 '19: -90K Q4 '19: -34K Q1 '20: -51K Q2 '20: 7K Q3 '20: 71K Q4 '20: 144K Q1 '21: 144K Q2 '21: 152K Q3 '21: 64K Q4 '21: 20K Q1 '22: 24K Q2 '22: 26K Q3 '22: 52K Q4 '22: -68K Q1 '23: -59K Q2 '23: -52K Q3 '23: -59K Q4 '23: 36K Q1 '24: 27K Q2 '24: 16K Q3 '24: 20K Q4 '24: 2K Q1 '25: -2K Q2 '25: 77K Q3 '25: 112K Q4 '25: 572K Q1 '26: 572K Q2 '26: 493K Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-6M -4M -2M 0 2M 4M 6M Q3 '16: -4.3M Q4 '16: -3.8M Q1 '17: -3.2M Q2 '17: -2.8M Q3 '17: -3.5M Q4 '17: -3.1M Q1 '18: -3M Q2 '18: -2.9M Q3 '18: -1.8M Q4 '18: -1.6M Q1 '19: -1.4M Q2 '19: -1.3M Q3 '19: -1.2M Q4 '19: -937K Q1 '20: -922K Q2 '20: -964K Q3 '20: -929K Q4 '20: -1.1M Q1 '21: -1.6M Q2 '21: -1.8M Q3 '21: -2.2M Q4 '21: -2.3M Q1 '22: -1.9M Q2 '22: -2.1M Q3 '22: -2.8M Q4 '22: -3.3M Q1 '23: -3.7M Q2 '23: -4.5M Q3 '23: -3.9M Q4 '23: -3.5M Q1 '24: -3M Q2 '24: -2.1M Q3 '24: -2.1M Q4 '24: -2.1M Q1 '25: -2.2M Q2 '25: -2.3M Q3 '25: -2.2M Q4 '25: -2.4M Q1 '26: -2.3M Q2 '26: -2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-15M -10M -5M 0 5M 10M 15M Q3 '15: -8.3M Q4 '15: -6.9M Q1 '16: -5.5M Q2 '16: -5.7M Q3 '16: -3.7M Q4 '16: -4M Q1 '17: -4.2M Q2 '17: -3.4M Q3 '17: -5.6M Q4 '17: -12.3M Q1 '18: -11.1M Q2 '18: -6.6M Q3 '18: -5M Q4 '18: 1M Q1 '19: -281K Q2 '19: -6.4M Q3 '19: -5.7M Q4 '20: -279K Q1 '21: -3.5M Q2 '21: 2.2M Q3 '21: 700K Q4 '21: -1.9M Q1 '22: -1.9M Q2 '22: -1.8M Q3 '22: -3M Q4 '22: -4.3M Q1 '23: -4.7M Q2 '23: -5.3M Q3 '23: -4.9M Q4 '23: -3.5M Q1 '24: -2.6M Q2 '24: -1.8M Q3 '24: -1.7M Q4 '24: -2M Q1 '25: -2.4M Q2 '25: -2.5M Q3 '25: -2.6M Q4 '25: -3.2M Q1 '26: -3.3M Q2 '26: -3.1M Q3 '16 Q4 '17 Q1 '19 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

-200K 0 200K 400K 600K Q4 '17: 530K Q1 '18: 517K Q2 '18: 436K Q3 '18: 339K Q4 '18: 90K Q1 '19: 88K Q2 '19: 152K Q3 '19: 152K Q4 '19: 70K Q1 '20: 69K Q2 '20: 10K Q3 '20: 22K Q4 '20: -42K Q1 '21: -42K Q2 '21: -48K Q3 '21: -18K Q4 '21: 61K Q1 '22: 62K Q2 '22: 63K Q3 '22: 21K Q4 '22: 81K Q1 '23: 89K Q2 '23: 121K Q3 '23: 125K Q4 '23: 62K Q1 '24: 55K Q2 '24: 22K Q3 '24: 18K Q4 '24: 5K Q1 '25: 3K Q2 '25: 41K Q3 '25: 66K Q4 '25: 195K Q1 '26: 195K Q2 '26: 157K Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '17: -678K Q4 '17: -1.1M Q1 '18: -1.1M Q2 '18: -1.5M Q3 '18: -1.7M Q4 '18: -1.4M Q1 '19: -1.2M Q2 '19: -1.1M Q3 '19: -913K Q4 '19: -806K Q1 '20: -1.1M Q2 '20: -1.4M Q3 '20: -1.7M Q4 '20: -1.9M Q1 '21: -1.7M Q2 '21: -1.9M Q3 '21: -2.1M Q4 '21: -1.6M Q1 '22: -1.5M Q2 '22: -1.1M Q3 '22: -981K Q4 '22: -1.5M Q1 '23: -1.8M Q2 '23: -1.9M Q3 '23: -1.7M Q4 '23: -1.7M Q1 '24: -1.3M Q2 '24: -1.1M Q3 '24: -1.1M Q4 '24: -1.1M Q1 '25: -1.4M Q2 '25: -1.3M Q3 '25: -1.1M Q4 '25: -1.1M Q1 '26: -1.4M Q2 '26: -1.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q2 '20: -1.4M Q3 '20: -1.7M Q4 '20: -1.9M Q1 '21: -1.7M Q2 '21: -2M Q3 '21: -2.1M Q4 '21: -1.6M Q1 '22: -1.5M Q2 '22: -1.1M Q3 '22: -1M Q4 '22: -1.5M Q1 '23: -1.8M Q2 '23: -1.9M Q3 '23: -1.8M Q4 '23: -1.7M Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '13: 65.7K Q3 '13: 66.3K Q1 '14: 71.5K Q2 '14: 73K Q3 '14: 77.7K Q1 '15: 973 Q2 '15: 107.3K Q3 '15: 2 Q1 '16: 109.9K Q2 '16: 41 Q3 '16: 283 Q1 '17: 946 Q2 '17: 1.9K Q3 '17: 6.9K Q1 '18: 2.5K Q2 '18: 2.7K Q3 '18: 394 Q1 '19: 3.2K Q2 '19: 3.3K Q3 '19: 3.3K Q1 '20: 65.6K Q2 '20: 11.9K Q3 '20: 60.3K Q1 '21: 13.2M Q2 '21: 13.3M Q3 '21: 13.4M Q1 '22: 20.7M Q2 '22: 26.3M Q3 '22: 34.8M Q1 '23: 49.3K Q2 '23: 51M Q3 '23: 51.5M Q1 '24: 54.8M Q2 '24: 56M Q3 '24: 57M Q1 '25: 68.3M Q2 '25: 78.8M Q3 '25: 81.7M Q1 '26: 88.8M Q2 '26: 96.5M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.21 -0.14 -0.07 0.00 0.07 0.14 0.21 Q4 '21: -0.17 Q1 '22: -0.18 Q2 '22: -0.13 Q3 '22: -0.16 Q4 '22: -0.16 Q1 '25: -0.05 Q2 '25: -0.05 Q3 '25: -0.05 Q4 '25: -0.04 Q1 '26: -0.04 Q2 '26: -0.04 Q4 '21 Q2 '22 Q4 '22 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.